Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round-up of R&D news in brief

Long acting Risperdal shines in study
Patients with first episode psychosis experienced significant improvements in their symptoms and social functioning after treatment with Janssen-Cilag's Risperdal Consta, according to research presented at a schizophrenia workshop in Switzerland.

The study said the long-acting injectable drug was found to be effective and generally well tolerated in people experiencing a first episode of psychosis.

ìIt is vitally important that a person's first experience of antipsychotic treatment is positive, as this can have a lasting impact on the individual's attitude to taking medication long-term,î said lead investigator, Professor Robin Emsley from the University of Stellenbosch, South Africa.

Question mark over anti-clotting treatment
The practice of treating heart-attack victims as soon as possible with anti-clotting drugs doesn't benefit patients and increases the risk of subsequent heart attacks and strokes, a new study published in the Lancet suggests.

The practice, known as ìfacilitated angioplastyî is a popular course of action while patients await the procedure to unblock their arteries, known simply as angioplasty.

In a pooled analysis, involving more than 4,500 patients, the two kinds of drugs commonly used in facilitated angioplasty were studied: the so-called IIb/IIIa inhibitors, which prevent blood-clot formation, and the thrombolytics, which dissolve existing blood clots.

Using the drugs within hours of angioplasty led to more deaths, more subsequent heart attacks, more episodes of major bleeding and more strokes than angioplasty by itself, the study found.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics